Organizing Committee:

Prof.Dr. HRH Princess Chulabhorn Mahidol Chairperson


In Thailand cancer is one of the main causes of death. With more than 110,000 new cases reported each year, cancer is now considered a major public health concern. Cancer affects Thai people both socially and economically. In males, the most common types of cancer are of the lungs, liver and bile duct, as well as colorectal and prostate cancer, and lymphoma. Among females, breast and cervical cancer, liver and bile duct cancer, and lung and colorectal cancer are the most common. Worldwide, lung cancer is the leading cause of cancer death; liver cancer is second. This is reflected in the Thai population generally, where liver and lung cancers are also among the most prevalent. The complex aetiology and often very poor treatment options in such cases, especially for liver cancer, underscore the urgent need to study both types of cancer in basic and clinical research settings.

Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol is founder and president of the Chulabhorn Research Institute, whose mission is to collaborate globally and to apply translational discoveries to improve the quality of life for all the people of Thailand. Her Royal Highness has initiated fruitful collaborative relationships with leading cancer laboratories around the world. In 2004, the Chulabhorn Cancer Centre was established in commemoration of the auspicious 72nd Birthday Anniversary of Her Majesty Queen Sirikit.

Under the gracious guidance of Her Royal Highness, the Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) project has been underway since 2008. TIGER-LC is a multi-institutional research which brings together the resources of the National Cancer Institutes of the United States and of Thailand, of the university hospitals of Khon Kaen and Chiang Mai Universities, and of Chulabhorn Hospital. The project is an on-going, comprehensive, large scale, genome-wide, and candidate-association study to identify and validate genomic risk factors associated with liver and bile duct cancer.

Emphasizing national and international collaboration across disciplines and between multiple institutes, the Scientific Symposium on “Current and Future Cancer Research: Liver and Lung Cancer” provides a platform for researchers and clinicians to come together, present, and discuss high-quality cancer research. Scientific topics span a breadth of disciplines, including cancer etiology, molecular biology, cancer prevention, early diagnosis, and functional and clinical studies. Bringing together such a spectrum of insights and perspectives could lead to significantly enhanced understanding about liver and lung cancer, eventually contributing to more successfully managed patient care and more precisely engineered medication. This symposium is another initiative to try to improve the quality of life of Thai cancer patients and to encourage and give hope to the people of Thailand. The participants from many countries and from diverse fields of cancer-related research have come, surely, with similar hopes of their own.